Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.67 |
| ▸ | LCK | P06239 | 4/20 | 0.67 |
| ▸ | JAK3 | P52333 | 4/20 | 0.67 |
| ▸ | TEK | Q02763 | 3/20 | 0.67 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | RAF1 | P04049 | 8/20 | 0.57 |
| ▸ | BRAF | P15056 | 10/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930157 | 0.93 | LCK (0.67) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL3937358 | 0.93 | KDR (0.66) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL14042145 | 0.86 | BRAF (0.73) | KDRMAPK14LCKMEN1RAB9A | |
| SCHEMBL4017741 | 0.85 | LCK (0.66) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL13198176 | 0.81 | KDR (0.66) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL3934490 | 0.81 | MAPK14 (0.76) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL13198190 | 0.80 | KDR (0.73) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL24123576 | 0.80 | LCK (0.81) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL5497472 | 0.80 | LCK (1.00) | KDRMAPK14LCKJAK3TEK | |
| SCHEMBL13198189 | 0.80 | KDR (0.77) | KDRMAPK14LCKJAK3TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | claimed |
| EP-2043638-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | claimed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | claimed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | claimed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | claimed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| EP-2043638-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | KDR 872/4885MAPK14 43/4885LCK 77/4885 |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | EPHB3, EPHB2, EPHB1 | KDR 1129/4885MAPK14 2431/4885LCK 433/4885 |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | ABL1, ERBB2, EPHB2 | KDR 105/4885MAPK14 88/4885LCK 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.